Protein Kinase C α Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells

Cancer Cell

Volumn 24, Issue 3, 2013, Pages 347-364

  Tam, Wai Leong ^a,f   Lu, Haihui ^a   Buikhuisen, Joyce ^a   Soh, Boon Seng ^b   Lim, Elgene ^c   Reinhardt, Ferenc ^a   Wu, Zhenhua Jeremy ^c   Krall, Jordan A ^a   Bierie, Brian ^a   Guo, Wenjun ^d   Chen, Xi ^e   Liu, Xiaole Shirley ^c   Brown, Myles ^c   Lim, Bing ^b   Weinberg, Robert A ^a,f  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; BISINDOLYLMALEIMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN C FOS; PROTEIN KINASE C ALPHA; PROTEIN KINASE C ALPHA INHIBITOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; CANCER STEM CELL; CONTROLLED STUDY; DRUG SCREENING; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE SWITCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; REGULATOR GENE; TARGET CELL DESTRUCTION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84883621632     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.005     Document Type: Article

References (38)

1. Abate C., Marshak D.R., Curran T. Fos is phosphorylated by p34cdc2, cAMP-dependent protein kinase and protein kinase C at multiple sites clustered within regulatory regions. Oncogene 1991, 6:2179-2185.
2. Ailles L.E., Weissman I.L. Cancer stem cells in solid tumors. Curr. Opin. Biotechnol. 2007, 18:460-466.
3. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
4. Blick T., Widodo E., Hugo H., Waltham M., Lenburg M.E., Neve R.M., Thompson E.W. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin. Exp. Metastasis 2008, 25:629-642.
5. Brabletz T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 2012, 12:425-436.
6. Buck E., Eyzaguirre A., Barr S., Thompson S., Sennello R., Young D., Iwata K.K., Gibson N.W., Cagnoni P., Haley J.D. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther. 2007, 6:532-541.
7. Cameron A.J., Escribano C., Saurin A.T., Kostelecky B., Parker P.J. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat. Struct. Mol. Biol. 2009, 16:624-630.
8. Carey L., Winer E., Viale G., Cameron D., Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 2010, 7:683-692.
9. Celià-Terrassa T., Meca-Cortés O., Mateo F., de Paz A.M., Rubio N., Arnal-Estapé A., Ell B.J., Bermudo R., Díaz A., Guerra-Rebollo M., et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J.Clin. Invest. 2012, 122:1849-1868.
10. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 2009, 106:13820-13825.
11. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annu. Rev. Med. 2007, 58:267-284.
12. Eferl R., Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 2003, 3:859-868.
13. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
14. Gould C.M., Antal C.E., Reyes G., Kunkel M.T., Adams R.A., Ziyar A., Riveros T., Newton A.C. Active site inhibitors protect protein kinase C from dephosphorylation and stabilize its mature form. J.Biol. Chem. 2011, 286:28922-28930.
15. Griner E.M., Kazanietz M.G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 2007, 7:281-294.
16. Gruda M.C., Kovary K., Metz R., Bravo R. Regulation of Fra-1 and Fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation invitro by MAP kinase affects DNA binding activity. Oncogene 1994, 9:2537-2547.
17. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
18. Kakumoto K., Sasai K., Sukezane T., Oneyama C., Ishimaru S., Shibutani K., Mizushima H., Mekada E., Hanafusa H., Akagi T. FRA1 is a determinant for the difference in RAS-induced transformation between human and rat fibroblasts. Proc. Natl. Acad. Sci. USA 2006, 103:5490-5495.
19. Kang J.H., Toita R., Kim C.W., Katayama Y. Protein kinase C (PKC) isozyme-specific substrates and their design. Biotechnol Adv. 2012, 30:1662-1672.
20. Kolch W., Heidecker G., Kochs G., Hummel R., Vahidi H., Mischak H., Finkenzeller G., Marmé D., Rapp U.R. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993, 364:249-252.
21. Lønne G.K., Cornmark L., Zahirovic I.O., Landberg G., Jirström K., Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol. Cancer 2010, 9:76.
22. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
23. Morel A.P., Lièvre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888.
24. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
25. Newton A.C. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev. 2001, 101:2353-2364.
26. Nieto M.A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol. 2011, 27:347-376.
27. Ocaña O.H., Córcoles R., Fabra A., Moreno-Bueno G., Acloque H., Vega S., Barrallo-Gimeno A., Cano A., Nieto M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22:709-724.
28. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., Bernard L., Viale G., Pelicci P.G., Di Fiore P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
29. Rhee S.G. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 2001, 70:281-312.
30. Saito Y., Hojo Y., Tanimoto T., Abe J., Berk B.C. Protein kinase C-alpha and protein kinase C-epsilon are required for Grb2-associated binder-1 tyrosine phosphorylation in response to platelet-derived growth factor. J.Biol. Chem. 2002, 277:23216-23222.
31. Sarrió D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008, 68:989-997.
32. Scheel C., Eaton E.N., Li S.H., Chaffer C.L., Reinhardt F., Kah K.J., Bell G., Guo W., Rubin J., Richardson A.L., Weinberg R.A. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
33. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
34. Stinson S., Lackner M.R., Adai A.T., Yu N., Kim H.J., O'Brien C., Spoerke J., Jhunjhunwala S., Boyd Z., Januario T., et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci. Signal. 2011, 4:ra41.
35. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
36. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., Iwata K.K., Gibson N., Haley J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005, 65:9455-9462.
37. Tsai J.H., Donaher J.L., Murphy D.A., Chau S., Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22:725-736.
38. Waddell N., Cocciardi S., Johnson J., Healey S., Marsh A., Riley J., da Silva L., Vargas A.C., Reid L., Simpson P.T., et al. Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. J.Pathol. 2010, 221:452-461. kConFab Investigators.